Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APS TSE:BU NASDAQ:DBTX NASDAQ:NEXI NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.68-5.1%C$1.66C$1.02▼C$17.40C$4.06M-0.1228584,924 shs8,464 shsBUBurcon NutraScienceC$2.27+0.4%C$2.41C$1.50▼C$5.00C$27.79M2.3063028,082 shs546 shsDBTXDecibel Therapeutics$4.91-0.8%$5.00$1.61▼$5.40$123.39M-0.43122,002 shs1.26 million shsNEXINexImmune$0.00$0.00▼$1.01N/A2.045,305 shsN/ASNSESensei Biotherapeutics$11.70-33.4%$9.28$5.00▼$18.35$22.17M0.3118,275 shs775,829 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences-5.08%+7.01%+1.82%-24.32%-88.45%BUBurcon NutraScience+0.44%+1.34%-5.81%-24.33%-21.72%DBTXDecibel Therapeutics0.00%0.00%0.00%0.00%0.00%NEXINexImmune0.00%0.00%-99.00%0.00%-99.97%SNSESensei Biotherapeutics-33.45%+3.91%+30.00%+49.23%+27.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.68-5.1%C$1.66C$1.02▼C$17.40C$4.06M-0.1228584,924 shs8,464 shsBUBurcon NutraScienceC$2.27+0.4%C$2.41C$1.50▼C$5.00C$27.79M2.3063028,082 shs546 shsDBTXDecibel Therapeutics$4.91-0.8%$5.00$1.61▼$5.40$123.39M-0.43122,002 shs1.26 million shsNEXINexImmune$0.00$0.00▼$1.01N/A2.045,305 shsN/ASNSESensei Biotherapeutics$11.70-33.4%$9.28$5.00▼$18.35$22.17M0.3118,275 shs775,829 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences-5.08%+7.01%+1.82%-24.32%-88.45%BUBurcon NutraScience+0.44%+1.34%-5.81%-24.33%-21.72%DBTXDecibel Therapeutics0.00%0.00%0.00%0.00%0.00%NEXINexImmune0.00%0.00%-99.00%0.00%-99.97%SNSESensei Biotherapeutics-33.45%+3.91%+30.00%+49.23%+27.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/ABUBurcon NutraScience 0.00N/AN/AN/ADBTXDecibel Therapeutics 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ASNSESensei Biotherapeutics 2.75Moderate Buy$55.00370.09% UpsideCurrent Analyst Ratings BreakdownLatest BU, APS, SNSE, DBTX, and NEXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025SNSESensei BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNSESensei BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/5/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.05 per share1.60C($0.92) per shareN/ABUBurcon NutraScienceC$273.38K105.36C$0.06 per share39.00C$0.02 per share92.45DBTXDecibel TherapeuticsN/AN/AN/AN/A$3.28 per shareN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$7.85N/A∞N/AN/A1,017.48%-136.29%N/ABUBurcon NutraScience-C$12.74M-C$3.47N/A∞N/A-1,758.62%-185.21%-39.22%N/ADBTXDecibel Therapeutics-$63.01M-$2.53N/AN/AN/AN/A-84.03%-53.90%N/ANEXINexImmune-$32.34M-$18.54N/AN/AN/AN/A-534.32%-213.72%N/ASNSESensei Biotherapeutics-$30.16M-$21.31N/AN/AN/AN/A-72.13%-61.35%11/13/2025 (Estimated)Latest BU, APS, SNSE, DBTX, and NEXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025SNSESensei Biotherapeutics-$4.11N/AN/AN/AN/AN/A8/5/2025Q2 2025SNSESensei Biotherapeutics-$6.20-$3.91+$2.29-$3.91N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/ABUBurcon NutraScienceN/A4.45%N/AN/AN/ADBTXDecibel TherapeuticsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41BUBurcon NutraScience187.905.631.71DBTXDecibel TherapeuticsN/A3.033.03NEXINexImmuneN/A0.660.66SNSESensei BiotherapeuticsN/A7.647.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences0.02%BUBurcon NutraScience0.05%DBTXDecibel Therapeutics69.59%NEXINexImmune9.85%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%BUBurcon NutraScience28.06%DBTXDecibel Therapeutics35.60%NEXINexImmune14.90%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences312.55 millionN/ANot OptionableBUBurcon NutraScience2012.69 millionN/ANot OptionableDBTXDecibel Therapeutics6825.13 million16.18 millionNot OptionableNEXINexImmune701.40 million1.19 millionNot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionableBU, APS, SNSE, DBTX, and NEXI HeadlinesRecent News About These CompaniesSensei Biotherapeutics reports results from Phase 1/2 trial of solnerstotugOctober 17 at 8:21 PM | msn.comSensei Biotherapeutics stock falls after Phase 1/2 trial resultsOctober 17 at 8:21 PM | za.investing.comSensei Biotherapeutics Reports Encouraging Phase 1/2 Trial Results of Solnerstotug in PD-(L)1 Refractory Cancer PatientsOctober 17 at 8:31 AM | quiverquant.comQSensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025October 17 at 8:00 AM | globenewswire.comSensei Biotherapeutics to Host Virtual KOL Event on Immunotherapy-Resistant Solid Tumors on October 20, 2025September 23, 2025 | quiverquant.comQSensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025September 23, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comSensei Biotherapeutics Inc trading resumesAugust 15, 2025 | msn.comSensei Biotherapeutics Inc trading halted, volatility trading pauseAugust 15, 2025 | msn.comSensei (SNSE) Q2 Loss Narrows 31%August 6, 2025 | fool.comSensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 5, 2025 | globenewswire.comThese 3 health tech stocks spiked 37% in a day; Time to buy?August 4, 2025 | finbold.comFSensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025July 30, 2025 | globenewswire.comSensei Biotherapeutics to execute 1-for-20 reverse stock splitJune 13, 2025 | kalkinemedia.comKSensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitJune 13, 2025 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressMay 6, 2025 | globenewswire.comSensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 2, 2025 | globenewswire.comSensei Biotherapeutics announces initial results from solnerstotug trial portionMarch 29, 2025 | markets.businessinsider.comSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caSensei Rockets on FY ’24 ResultsMarch 28, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Downgraded But Not Done: 3 Stocks Ready for a Market ComebackBy Thomas Hughes | September 24, 2025Qualcomm’s RSI Just Hit Its High of the Year—Why That’s BullishBy Sam Quirke | September 24, 2025Top Insider Buys and Sells From September: Buy, Sell, or Hold?By Thomas Hughes | September 29, 2025Rocket Lab’s Bullish Case Remains Intact Despite Recent OfferingBy Ryan Hasson | September 24, 2025BU, APS, SNSE, DBTX, and NEXI Company DescriptionsAptose Biosciences TSE:APSC$1.68 -0.09 (-5.08%) As of 10/17/2025 01:17 PM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Burcon NutraScience TSE:BUC$2.27 +0.01 (+0.44%) As of 10/17/2025 03:53 PM EasternBurcon is a global technology leader in the development of plant-based proteins. With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives. Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.Decibel Therapeutics NASDAQ:DBTXDecibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.NexImmune NASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Sensei Biotherapeutics NASDAQ:SNSE$11.70 -5.88 (-33.45%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$10.76 -0.94 (-8.07%) As of 10/17/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
